Sugi Predict

Sugi Predict / Compounds / SCHEMBL5756703

SCHEMBL5756703

SCHEMBL5756703

CC1(O)CCCN(S(=O)(=O)c2ccc(OCc3ccc(F)cc3)cc2)C1C(=O)O

nearest known ligand 0.81

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MMP1 P03956 20/20 0.81
▸ ADAM17 P78536 8/20 0.81
▸ ADAMTS4 O75173 1/20 0.61
▸ TNF P01375 1/20 0.61
▸ MMP2 P08253 1/20 0.61
▸ MMP3 P08254 1/20 0.61
▸ MMP9 P14780 1/20 0.61
▸ MMP8 P22894 1/20 0.61
▸ MMP13 P45452 1/20 0.61
▸ MMP14 P50281 1/20 0.61
▸ ADAMTS1 Q9UHI8 1/20 0.61
▸ ADAMTS5 Q9UNA0 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7507355 1.00 MMP1 (0.81) MMP1ADAM17ADAMTS4TNFMMP2
SCHEMBL5758021 0.90 MMP1 (1.00) MMP1ADAM17ADAMTS4TNFMMP2
SCHEMBL5757881 0.90 MMP1 (1.00) MMP1ADAM17ADAMTS4TNFMMP2
Hydroxyamine SCHEMBL5894322 0.89 MMP1 (0.66) MMP1ADAM17
SCHEMBL5760716 0.89 MMP1 (0.82) MMP1ADAM17ADAMTS4TNFMMP2
SCHEMBL5757331 0.88 MMP1 (0.75) MMP1ADAM17ADAMTS4TNFMMP2
SCHEMBL14639265 0.86 MMP1 (0.83) MMP1ADAM17ADAMTS4TNFMMP2
SCHEMBL1817324 0.86 MMP1 (0.83) MMP1ADAM17ADAMTS4TNFMMP2
SCHEMBL17479343 0.86 MMP1 (0.83) MMP1ADAM17ADAMTS4TNFMMP2
SCHEMBL28941391 0.86 MMP1 (0.83) MMP1ADAM17ADAMTS4TNFMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1104403-A1 HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS Pfizer Products Inc. (US) 2001-06-06 — — EP claimed
WO-2000009485-A1 HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS PFIZER PRODUCTS INC. (US) 2000-02-24 — — WO claimed
EP-1104403-B1 HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS PFIZER PROD INC (US) 2006-05-10 — — EP disclosed
US-20030008901-A1 Hydroxy pipecolate hydroxamic acid derivatives MCCLURE KIM F (US) 2003-01-09 — — US disclosed
US-6329397-B1 TREATMENT OF A CONDITION SELECTED FROM THE GROUP CONSISTING OF ARTHRITIS, CANCER, AND OTHER DISEASES CHARACTERIZED BY MATRIX METALLOPROTEINASE OR MAMMALIAN REPROLYSIN ACTIVITY. PFIZER 2001-12-11 — — US disclosed
CN-1316995-A Hydroxy 2-piperidinoate hydroxamic acid derivatives as MMP inhibitors PFIZER PROD INC (US) 2001-10-10 — — CN disclosed
EP-1104403-A1 HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS Pfizer Products Inc. (US) 2001-06-06 — — EP disclosed
WO-2000009485-A1 HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS PFIZER PRODUCTS INC. (US) 2000-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008901-A1 Hydroxy pipecolate hydroxamic acid derivatives MMP1, MMP10, MMP3 MMP1 1/4885ADAM17 221/4885ADAMTS4 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.